26
Aug
2016

EpiPen Pricing Fury, Pfizer’s $14B Megabid for Medivation & Denali Grabs $130M

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Bluebird Fire Sale, Regeneron’s Gene Therapy for Deafness, & Eikon Raises a Bundle
Defend Young Scientists
Defend the FDA
RFK Jr. in Power, NIH and FDA on the Chopping Block, & Interest Rates Loom Large